We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The legalities and overall effect of special out-of-court settlements that result in lengthening the period of exclusivity for a brand drug by stalling generic entry are up for debate on Capitol Hill as members of the Senate Judiciary Committee plan to hold a hearing scheduled for Jan. 17, congressional sources say.